ALFRESCO-SOFTWARE
8.10.2014 07:01:11 CEST | Business Wire | Pressemeddelelse
Alfresco Software today announced it is contributing to the Apache Software Foundation an open source integration, named Chemistry Parts. The integration connects Microsoft SharePoint to virtually any enterprise content management (ECM) system, including Alfresco, using the open standard CMIS (Content Management Interoperability Services) from OASIS. The integration is contributed by Alfresco to the Apache Chemistry project, which is an open source implementation of CMIS.
Chemistry Parts is based on a configurable framework and Microsoft SharePoint Web Parts provided as an open source CMIS client implementation. Using Chemistry Parts, developers can quickly and easily create their own content solutions that connect to multiple content repositories and are accessible from Microsoft SharePoint. Implemented using simple, lightweight HTML5 JavaScript, developers create new solutions through configuration alone. Applications such as document libraries, records management, imaging applications and process applications can integrate with SharePoint yet have the scalability and compliance found in Alfresco or another ECM platform.
Alfresco has worked with Armedia, an Atlanta-based services company specializing in content solutions, to create the SharePoint integration. Jim Nasr, CEO of Armedia said, “We have seen a lot of demand for this type of integration with our US Federal customers. The widespread use of SharePoint in the government and the availability of this framework provide an opportunity to solve some real content problems that have not been addressed. We are proud to have worked with Alfresco on making this framework available as open source.”
Florian Mueller, Vice President of Apache Chemistry commented, “The Apache Chemistry project has been proud to be the de facto reference implementation of CMIS. I am really happy to see the interoperability that this framework provides between SharePoint and other CMIS implementations.”
Alan Pelz-Sharpe, Research Director at 451 Research, commented, “There is almost never one content management system in medium-to-large enterprises, but the majority have some sort of implementation of SharePoint. There is clearly a need for SharePoint and ECM to coexist and cooperate. An open source and open standards approach could be a promising way for that coexistence to work.”
Alfresco Founder and CTO John Newton said, “The time is right for this type of framework. We have been big supporters of CMIS and Apache Chemistry precisely to encourage this type of development of new, interoperable content solutions. Our customers that are also users of Microsoft SharePoint will benefit from solutions built from this framework.”
CMIS was created as an open standard and proposed to OASIS in 2008 by IBM, EMC, Microsoft, SAP, OpenText and Alfresco. Considered the “SQL of Content Management”, the standard defines application programming interfaces (APIs) that can query, update and manage content in repositories such as IBM FileNet, EMC Documentum, Microsoft SharePoint and Alfresco. CMIS is the content integration standard of choice of companies like IBM and SAP.
About Alfresco Software
Alfresco provides modern, enterprise content management (ECM) software built on open standards that enables organizations to unlock the power of their business-critical content. With the controls that IT demands and the simplicity that end users love, Alfresco's open source technology enables global organizations to collaborate more effectively across cloud, mobile, hybrid and on-premise environments. More than 1,800 organizations in 212 countries turn to Alfresco for its hybrid, enterprise-grade platform. Innovating at the intersection of content, collaboration and business process, Alfresco manages over seven billion documents, powering the daily tasks of more than 11 million users worldwide. Select Alfresco customers include: Amnesty International, Cisco, DAB Bank, FOX, NASA, PGA TOUR, and Sony Entertainment. Founded in 2005, Alfresco’s UK headquarters are in Maidenhead, UK with U.S. headquarters in San Mateo, CA. Please visit us at: http://www.alfresco.com
Contact:
Alfresco Software
Kathleen Reidy, +1-857-231-1988
kathleen.reidy@alfresco.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
